Production baseline verification recorded.
Global Phase 3 MASH development
LATE STAGE PIPELINE
Pemvidutide
Broadens peptide readiness beyond weight loss into liver disease and the convergence of metabolic and hepatology pathways.
FDA STATUS
Investigational; FDA Breakthrough Therapy designation does not equal approval
PROFESSIONAL RELEVANCE
Track MASH endpoints, regulatory alignment, hepatology pathways and future NICE value questions.
Product, formulation and indication
No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.
Status history
Future material changes will be appended with their previous status and source; they will not be silently overwritten.
Verify this record
Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.